The development of a highly sensitive mouse monoclonal antibody for screening ALK-rearrangements in lung cancers

Jian Chen, Mulan Jin, Yi Shen, Yipan Wu, Kehu Yuan, Boyang Chu, Lili Qi, Huibo Liu, Yuechao Gu, Guangli Wang, Youmin Shu, Julie McDowell, Donghui Ma & Wei-wu He OriGene Technologies, 9620 Medical Center Dr., Rockville, MD 20850

Abstract

The anaplastic lymphoma kinase (ALK) rearrangements, mostly EML4-ALK fusion, occur in 3-7% of lung cancer patients and define a patient population that could respond to receptor tyrosine kinase inhibitor Crizotinib and Ceritinib. Currently, ALK testing is mostly conducted by either fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) methods, either of which has its own limitations. The detection of the ALK protein in lung cancer patient tissues by IHC was found to be difficult mostly due to the low abundance of its fusion product. To overcome this limitation, we have developed an ALK mouse monoclonal antibody (clone 1A4) that is more sensitive than a current rabbit ALK antibody D5F3. Our initial analyses revealed that 1A4 can correctly identify all 5 EML4-ALK positive samples that were previously confirmed by QPCR tests, while did not yield significant background on all 30 EML4-ALK negative lung cancer samples. By using a different IHC detection system, we further tested 1A4 on 17 ALK-positive and 10 ALK-negative lung cancer biopsy specimens that have been validated by either FISH or PCR from another hospital. The IHC result of the antibody 100% agreed with the previous molecular diagnosis. The high concordance of the IHC results by the novel ALK antibody with other DNA/RNA based detection methods suggested that 1A4 could be used routinely for screening ALK-rearrangement genetic events among patients.

Background



Fusion protein	Tumor type	Frequency (%)
EML4-ALK	NSCLC	6
KLF5B-ALK	NSCLC	0.5
KLC1-ALK	NSCLC	Unknown
NPM-ALK	ALCL and DLBCL	75-80
TPM3-ALK	ALCL and IMT	12-18

ALCL, anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma; IMT, inflammatory myofibroblastic tumours; NSCLC, non-small-cell lung cancer.

Lung cancer and different forms of ALK translocation. (A). Top20 human cancer type around the world. Lung cancer is the most frequent cancer type (WCRF, 2008) (B). Top oncogenic molecular mutations in lung adenocarcinomas. (C). Schema of ALK fusion protein resulted from ALK translocations and representative ALK translocation events in lymphomas and lung cancer. (D). Frequency of different EML4-ALK translocation varieties reported in NSCLC.

Background

A



Percentage of tumor response, treatment duration, and smoking history. Selected tumor characteristics are listed in the table below the graph, with each table entry corresponding to a patient in the graph above [2].

Generating an ALK IHC antibody



Generating a high-affinity ALK antibody for IHC application. (A). A hybridoma screening process to select antibodies that recognize ALK fusion proteins in lung cancer cells. (B). The ALK antibody 1A4 clone recognized full length ALK protein that was transfected and expressed in 293T cells. (C). The ALK antibody 1A4 recognized ALK fusion protein in lung cancer cell line H2228 at the dilution of 1:10,000 (D). IHC staining of ALK-positive anaplastic large cell lymphoma (ALCL) tissue and paraffin embedded xenograft tissue derived from H2228 cells.

Comparison between 1A4 and D5F3



Sensitivity comparison between 1A4 and D5F3. IHC staining result of D5F3 and 1A4 on ALK-positive NSCLC samples using a detection system from GBI-lab (PV9000).

1A4 staining and ALK status



Correlation of 1A4 staining with ALK translocation determined by QPCR. (A). A scheme of screening ALK+ patient from OriGene's tissue bank and the summary of IHC validation result. (B). Representative pictures of 1A4 staining on ALK+ lung adenocarcinoma tissues. (C). Representative pictures of 1A4 staining on ALK negative lung adenocarcinoma. (D). 1A4 staining on myofibroblastic stomach tumor.

1A4 staining and ALK FISH results

A

Patient ID	FISH	PCR	1A4 IHC	Comments
shi/312038-8	+	+	+	EML4-ALK
shi/289984-1	+	+	+	EML4-ALK
shi/309348-2	+	+	+	EML4-ALK
shi/239323-2	+	+ / -	+	EML4-ALK
shi/295879-1	+	/	+	
shi/290577-25	+	-	+	
shi/306208-6	+	-	+	
shi/305449-1	+	/	+	
347141-1 shi	+	/	+	
295025-17 shi	+	-	+	
shi/269666-1	-	+	+	EML4-ALK
shi/269093	failed	+ / -	+	EML4-ALK
shi/296428-2	failed	+	+	EML4-ALK
shi/271544-4	failed	+	+	EML4-ALK
shi/336960-1	-	+	+	EML4-ALK
Shi/339053-4	-	+	+	EML4-ALK
shi/339053-4	NA	-	-	
shi/347408-2	NA	-	-	
shi/348306-3	NA	-	-	
shi/348030-7	NA	-	-	
shi/349256-7	NA	-	-	
shi/348920-2	NA	-	-	
shi/348307-4	NA	-	-	
shi/343708-2	NA	-	-	
shi/332715-4	NA	-	-	
shi/340837-2	NA	-	-	
shi/341071-5	NA	-	-	

B



C



1A4 staining result correlates with ALK FISH and QPCR result in lung adenocarcinoma sample set from Beijing Chaoyang Hospital. (A). Summary of the ALK diagnosis result by different techniques. (B). Representative 1A4 staining of the ALK+ lung adenocarcinoma. (C). Representative 1A4 staining of the ALK-negative lung adenocarcinoma.

More sensitive ALK antibody cocktails



Development of more sensitive ALK IHC antibodies by mixed several clones of ALK antibodies. Two cocktail recipes showed higher sensitivity than 1A4 using a relative insensitive detection system..

References

1. Ma D, et al. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnology, 2012, 12: 88
2. Kwak EL, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. New England Journal of Medicine, 2010, 363(18): 1693-1703.
3. Shaw AT, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The lancet oncology, 2011, 12(11): 1004-1012.